Atriva Therapeutics

@AtrivaTx

Clinical stage biopharmaceutical company developing host-targeting inhibitors against respiratory viral infections.

Tübingen, Germany
Vrijeme pridruživanja: listopad 2019.

Tweetovi

Blokirali ste korisnika/cu @AtrivaTx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AtrivaTx

  1. prije 3 sata

    ausbremsen! Medikamentös gegen ! Atriva in diesem Artikel aus vorgestellt the ! Medication against !

    Poništi
  2. 5. velj

    Biopharma companies, academics, governments racing to develop medical countermeasures against novel - A good summary of the last 15 days

    Poništi
  3. proslijedio/la je Tweet

    Based on data as of 24:00 on Feb 3, the mortality rate of the outbreak of in China, except Hubei Province, was 0.16%. The mortality rate in Hubei Province, the epicenter of the outbreak, was 3.1% while the figure in Wuhan was 4.9%.

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet
    4. velj

    The Coronavirus outbreak: Letter from the Editor. — coverage on biomedical countermeasures; effect on clinical trials and supply chain; and more. Free to all, no paywall.

    Poništi
  5. 3. velj

    Knowledge and science have no borders. Scientists and experts of all World are working together to find a solution to beat . German scientists are also contributing by working and sharing results.

    Poništi
  6. 3. velj

    “. is working on ways to block viral activity. Dr. Lichtenberger, CEO, told that the company’s approach involved inhibiting the pathway which is used by RNA viruses like when they replicate within cells.”

    Poništi
  7. proslijedio/la je Tweet
    3. velj

    How credible do you think the current reports regarding the Novel Acute Respiratory Disease?

    Poništi
  8. 2. velj

    As the spreads, fear is fueling racism and - CNN. This is not the they. We need to fight and not against each other.

    Poništi
  9. proslijedio/la je Tweet

    China initially put secrecy and order ahead of confronting the coronavirus. The New York Times reconstructed the crucial 7 weeks when it grew into a crisis.

    Poništi
  10. 31. sij

    Die von . entwickelte Substanz blockiert die Kommunikation zwischen Viren und Körperzellen und kann so effektiv gegen ein breites Spektrum von Viren eingesetzt werden. Atriva ist es gelungen, die Vermehrung von SARS und eines in Zellkulturen zu verhindern.

    Poništi
  11. 30. sij

    Prof. Ludwig ist ein großartiger Wissenschaftler und Kollaborator. Seit Jahren arbeiten wir erfolgreich mit ihm zusammen, um gegen zu entwickeln.

    Poništi
  12. proslijedio/la je Tweet
    29. sij

    Atriva Fast Tracks Antiviral Candidate As Coronavirus Arrives In Germany

    Poništi
  13. 29. sij

    The world is under virus attack, but German scientists are already on the move. spoke with Prof. Dr. Ludwig, developer of ’ host-targeting candidate, , about pandemic threats like , SARS, MERS and .

    Poništi
  14. 15. sij

    The 3rd and last conference during the ’s San Francisco tour is the 15th Non-Dilutive Funding Summit . Meet our representatives to learn more about our potential in the development of host-targeting therapies.

    Poništi
  15. 14. sij

    We look forward to telling you more about , our host-targeting approach to treat , at the RESI conference, where 500+ early stage investors gather every year. Dr. Rainer Lichtenberger will present Atriva during the track 4, 8:00 am.

    Poništi
  16. proslijedio/la je Tweet
    13. sij

    'Good Morning from 2020! is on site in San Francisco, excited for three days of presentations, panels and 1X1 meetings at one of the industry's leading investor conferences. We're looking forward to meeting you!

    Poništi
  17. 13. sij

    Learn more about ’s host-targeting therapy candidate against , hanta and further severe respiratory viral infections at the company presentation of our CEO, Dr. Lichtenberger, today at . Join us at 11:30, Franciscan D.

    Poništi
  18. 9. sij

    kicks off the new year by travelling to to participate in three conferences. Dr. Lichtenberger, CEO, Dr. Wallasch, COO, and Dr. Björn Cochlovius, VP BD, will represent the Company and be available for networking and one-on-ones.

    Poništi
  19. proslijedio/la je Tweet
    23. pro 2019.

    During this holiday season relax and enjoy the time with family and friends and don't forget to register for in : January 13-15, 2020. . will be on site to support you! We hope to see you there!

    Poništi
  20. 20. pro 2019.

    is always lurking, especially during the winter season, which impairs our immune system. At , we are developing a unique portfolio of broadly active and efficacious antiviral drugs. Stay warm and enjoy the . and from Atriva.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·